<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>713</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15734548</PubmedId>
            <Abstract>In this study a synthetic peptide representing residues 141-159 from the GH loop of VP1 protein of foot-and-mouth disease virus was tested for its capacity to elicit virus neutralising antibodies in mice after transcutaneous immunisation. Topical application of the peptide conjugated to bovine serum albumin together with cholera toxin as an adjuvant elicited anti-peptide antibody responses with strong virus neutralising activity. The combination of cholera toxin with an immunostimulatory CpG motif resulted in the induction of IgG1 and IgG2a anti-peptide antibodies with significantly enhanced virus neutralising activity. To shed more light on the mechanisms of cholera toxin adjuvanticity we demonstrated its binding to keratinocytes via GM(1)-gangliosides. This was followed by an increase of the intracellular cAMP and the rapid diffusion of cholera toxin throughout the epidermis. These findings demonstrate that peptide-based vaccines when combined with the appropriate adjuvant(s) can elicit potent virus neutralising antibody responses after transcutaneous immunisation. However, experiments in target species will be required to confirm the potential of this simple vaccination procedure in livestock.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>273-80</ArticlePages>
            <ArticleTitle>A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Beignon</LastName>
                    <ForeName>Anne-Sophie</ForeName>
                </Author>
                <Author>
                    <LastName>Brown</LastName>
                    <ForeName>Fred</ForeName>
                </Author>
                <Author>
                    <LastName>Eftekhari</LastName>
                    <ForeName>Pierre</ForeName>
                </Author>
                <Author>
                    <LastName>Kramer</LastName>
                    <ForeName>Ed</ForeName>
                </Author>
                <Author>
                    <LastName>Briand</LastName>
                    <ForeName>Jean-Paul</ForeName>
                </Author>
                <Author>
                    <LastName>Muller</LastName>
                    <ForeName>Sylviane</ForeName>
                </Author>
                <Author>
                    <LastName>Partidos</LastName>
                    <ForeName>Charalambos D</ForeName>
                </Author>
            </Authors>
            <ArticleChemicalList>Adjuvants, Immunologic;Antibodies, Viral;Capsid Proteins;Peptide Fragments;VP1 protein, Foot-and-mouth disease virus;Vaccines, Subunit;Viral Vaccines;Cholera Toxin;Cyclic AMP</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adjuvants, Immunologic(pharmacology); Administration, Cutaneous; Animals; Animals, Domestic; Antibodies, Viral(blood); Biopsy; Capsid Proteins(immunology); Cholera Toxin(immunology); Cyclic AMP(immunology); Female; Flow Cytometry; Foot-and-Mouth Disease(immunology; prevention &amp; control); Foot-and-Mouth Disease Virus(immunology); Immunohistochemistry; Keratinocytes(immunology); Mice; Mice, Inbred BALB C; Peptide Fragments(immunology); Vaccines, Subunit(immunology; standards); Viral Vaccines(administration &amp; dosage; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>104</Volume>
                <Issue>3-4</Issue>
                <Title>Veterinary immunology and immunopathology</Title>
                <Issn>0165-2427</Issn>
                <MedlineTa>Vet Immunol Immunopathol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Peptide 141-159</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GSGVRGDFGSLAPRVARQL</LinearSequence>
                        <StartingPosition>864</StartingPosition>
                        <EndingPosition>882</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03308.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>12114</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>22360</EpitopeId>
                <ReferenceStartingPosition>141</ReferenceStartingPosition>
                <ReferenceEndingPosition>159</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>7194</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GSGVRGDFGSLAPRVARQL</LinearSequence>
                                            <StartingPosition>864</StartingPosition>
                                            <EndingPosition>882</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03308.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>12114</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Peptide 141-159</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P02769.4</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>9913</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>CpG</Adjuvant>
                                <Adjuvant>Other</Adjuvant>
                                <Route>Transcutaneous</Route>
                                <DoseSchedule>4 dose(s) of 100 ug vaccine/30 ul solution</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Vaccines used: 1) epitope-BSA, 2) epitope-BSA with cholera toxin (CT, Other in the adjuvant entry), 3) epitope-BSA with CT and CpG, and 4) epitope-BSA with CT and non-CpG. Boosters were given on days 21, 42 and 63."".</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Serum samples were drawn 1 week after booster. All vaccines utilized gave an antibody response. The predominant isotype after 3rd boost in the presence of CT is IgG1 (ratio of IgG1/IgG2a=22.5), whereas combination of CT with CpG shifted the subclass profile towards a more balanced response (ratio IgG1/IgG2a=5).</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Light Isotype n/s</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Peptide 141-159</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GSGVRGDFGSLAPRVARQL</LinearSequence>
                                        <StartingPosition>864</StartingPosition>
                                        <EndingPosition>882</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03308.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>12114</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Protein conjugate</ComplexType>
                                    <PeptideModifications/>
                                    <SourceMolecule>
                                        <GenBankId>P02769.4</GenBankId>
                                    </SourceMolecule>
                                    <MoleculeSourceOrganismId>9913</MoleculeSourceOrganismId>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>7195</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GSGVRGDFGSLAPRVARQL</LinearSequence>
                                            <StartingPosition>864</StartingPosition>
                                            <EndingPosition>882</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03308.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>12114</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Peptide 141-159</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P02769.4</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>9913</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>CpG</Adjuvant>
                                <Adjuvant>Other</Adjuvant>
                                <Route>Transcutaneous</Route>
                                <DoseSchedule>4 dose(s) of 100 ug vaccine/30 ul solution</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Vaccines used: 1) epitope-BSA, 2) epitope-BSA with cholera toxin (CT, Other in the adjuvant entry), 3) epitope-BSA with CT and CpG, and 4) epitope-BSA with CT and non-CpG. Boosters were given on days 21, 42 and 63."".</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Serum samples were drawn 1 week after booster. All vaccines utilized had neutralizing activity against the virus; in particular, neutralizing activity was significantly better with the use of CT and CpG. The predominant isotype after 3rd boost in the presence of CT is IgG1 (ratio of IgG1/IgG2a=22.5), whereas combination of CT with CpG shifted the subclass profile towards a more balanced response (ratio IgG1/IgG2a=5).</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Light Isotype n/s</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Foot-and-mouth disease virus</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>12114</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

